We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) ...

Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of ...

Women with endometrial cancer who are found to have lymph-node-positive disease during surgical staging by lymphadenectomy benefit from adjuvant chemotherapy; however, the remaining 78% of women who ...

Silence Therapeutics PLC ADR Annual stock financials by MarketWatch. View the latest SLN financial statements, income statements and financial ratios.

Silence Therapeutics plc's Zerlasiran showed significant Lp(a) reduction but was overshadowed by Eli Lilly's oral Muvalaplin, which offers similar efficacy with easier administration and potentially ...

Surgical treatment for breast cancer involves removal of the lymph nodes and can also include resection of the surrounding axillary nodes. The more invasive procedure of axillary-lymph-node dissection ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Amazon India today launched its Seller Lending Network (SLN), which will allow sellers on the e-commerce major's platform to seek loans from multiple third party lenders. (Reuters) Amazon India today ...

SLN is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of SLN shares has increased $0.05 since the market last closed. This is a 0.69% ...